Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Ekso Bionics Holdings Inc Market Cap
Based on ratings from 2 stock analysts, the Ekso Bionics Holdings Inc stock price is expected to increase by 685.71% in 12 months. This is calculated by using the average 12-month stock price forecast for Ekso Bionics Holdings Inc. The lowest target is $2 and the highest is $9. Please note analyst price targets are not guaranteed and could be missed completely.
Ekso Bionics Holdings Inc has a total of 2 Wall St Analyst ratings. There are 2 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Ekso Bionics Holdings Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of EKSO.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Ben Haynor Lake Street | Buy | $2 | Maintains | Oct 29, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $9 | Maintains | Oct 29, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $10 | Reiterates | Jul 30, 2024 |
| Ben Haynor Lake Street | Buy | $2.5 | Initiates | Jun 24, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $10 | Maintains | Apr 30, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $9.25 | Maintains | Mar 5, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $10 | Maintains | Jan 22, 2024 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $9 | Reiterates | Apr 28, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $9 | Reiterates | Mar 30, 2023 |
| Swayampakula Ramakanth HC Wainwright & Co. | Buy | $9 | Maintains | Jul 29, 2022 |
Cantor Fitzgerald | Overweight | Maintains | Nov 25, 2020 | |
H.C. Wainwright | Buy | Initiates | Nov 25, 2020 | |
B. Riley FBR | Buy | Initiates | Nov 25, 2020 | |
HC Wainwright & Co. | Buy | Maintains | Nov 25, 2020 | |
Aegis Capital | Buy | Maintains | Nov 25, 2020 | |
SunTrust Robinson Humphrey | Buy | Initiates | Nov 25, 2020 | |
HC Wainwright & Co. | Buy | $11 | Maintains | Oct 30, 2020 |
Aegis Capital | Buy | $9 | Maintains | Aug 3, 2020 |
HC Wainwright & Co. | Buy | $12 | Maintains | Jun 26, 2020 |
HC Wainwright & Co. | Buy | $8 | Maintains | Jun 15, 2020 |
When did it IPO
2014
Staff Count
70
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Scott G. Davis
Market Cap
$15.2M
In 2023, EKSO generated $18.3M in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that EKSO's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) announced that Katherine Strausser will participate in an 'AI for Good' webinar, highlighting the company's engagement in exoskeleton technology.
Why It Matters - Katherine Strausser's participation in the 'AI for Good' webinar highlights Ekso Bionics' commitment to innovation, potentially enhancing its reputation and attracting investor interest.
Tue, 12 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) executives will present at the Craig-Hallum Alpha Select Conference in New York on November 19, 2024.
Why It Matters - Ekso Bionics' participation in a prominent conference highlights its visibility and potential growth in the exoskeleton market, influencing investor sentiment and stock performance.
Mon, 28 Oct 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) will hold its Q3 2024 earnings conference call on October 28, 2024, at 4:30 PM ET, featuring key company executives and analysts.
Why It Matters - Ekso Bionics' Q3 earnings call provides insights into financial performance and future strategies, crucial for assessing its market position and potential growth, impacting investment decisions.
Mon, 28 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) reported its financial results for Q3 and the first nine months of 2024, highlighting its position in exoskeleton technology for medical and industrial applications.
Why It Matters - Ekso Bionics' financial results can impact stock performance, signaling growth potential or operational challenges, influencing investor sentiment and market valuation.
Mon, 28 Oct 2024
Sentiment - NEGATIVE
Source - Zacks Investment Research
Summary - Ekso Bionics (EKSO) reported a quarterly loss of $0.10 per share, worse than the expected loss of $0.08, but improved from a loss of $0.24 per share a year earlier.
Why It Matters - Ekso Bionics' larger-than-expected quarterly loss signals ongoing financial challenges, potentially impacting investor confidence and stock performance.
Mon, 21 Oct 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ekso Bionics Holdings, Inc. will release its Q3 2024 financial results on October 28, 2024, followed by a conference call at 1:30 p.m. PT to discuss the results and business updates.
Why It Matters - Ekso Bionics' upcoming Q3 2024 results and conference call will reveal key financial performance and strategic direction, influencing stock performance and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
